Endeavour Vision, a venture capital and growth equity firm, closed the Endeavour Medtech Growth II (EMG II) LP fund, at USD 375m.
Both new and returning investors supported EMG II LP, including public pension funds, multi-manager funds, family offices and high-net-worth individuals.
Led by managing partners Bernard Vogel or Damien Teppy, Endeavour Medtech Growth II (EMG II) LP will invest in growth-stage medtech and digital health innovations that advance the standard of care and bring efficiencies to healthcare systems.
The fund’s closing comes as the world begins to look towards post-pandemic life after more than 12 months in the grip of COVID-19, a crisis that has accelerated the adoption of new healthcare technologies including novel ways of delivering remote patient care. Underlying trends, such as ageing populations, chronic diseases and strained healthcare budgets will continue to fuel demand for cost-efficient solutions.
The fund has already supported seven companies with investments totalling more than USD 100m: IntelyCare, CeQur, Rapid Micro Biosystems, SOPHiA GENETICS, Nalu Medical, Lumeon and Relievant Medsystems.
EMG II LP builds on Endeavour Vision’s two decades of healthcare investing, which to date has included over USD 500 million invested in 42 companies—21 of which have exited via an acquisition or IPO.
The firm’s international investment teams are based in two global healthcare hubs in Geneva, Switzerland, and Minneapolis, US.